Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090103 · ClinicalTrials.gov registry record · Phase 3
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
A Phase 3 study of Prostatic Hyperplasia, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,844
- Enrollment target
- 20
- Study locations
NCT00090103: Completed Phase 3 study of Prostatic Hyperplasia, sponsored by GlaxoSmithKline.
NCT00090103 is a Phase 3 study of Prostatic Hyperplasia that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,844 participants, above the 2,092-participant average among 5 other Prostatic Hyperplasia trials with a reported enrollment target (132% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00090103, a Phase 3 study of Prostatic Hyperplasia, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,844 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually.
Primary Outcome
A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.
Conditions Studied
Interventions
- DRUG dutasteride 0.5mg once daily for 4 years
- DRUG tamsulosin 0.4mg once daily for 4 years
Study Locations (20)
California
- GSK Investigational Site - Beverly Hills
- GSK Investigational Site - Concord
- GSK Investigational Site - Glendora
- GSK Investigational Site - Greenbrae
- GSK Investigational Site - Irvine
- GSK Investigational Site - La Jolla
- GSK Investigational Site - Laguna Woods
- GSK Investigational Site - Los Angelas
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Modesto
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Columbiana
- GSK Investigational Site - Hoover
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix, Arizona
Alaska
- GSK Investigational Site - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,844 participants |
| Start Date | 2003-11 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00090103 record still lists
NCT00090103 is an interventional study that assigns participants to a tested intervention. Its 4,844 participants enrollment target places it among the larger protocols in the corpus, above the 2,092-participant average among 5 other Prostatic Hyperplasia trials with a reported enrollment target (132% higher).
The record links to 1 condition, with Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which dutasteride 0.5mg once daily for 4 years is the first listed.
NCT00090103 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00090103 about?
NCT00090103 is a clinical study titled "Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment". This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study vi...
What is the current status of trial NCT00090103?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,844 participants. The study started on 2003-11. Estimated completion is 2009-04.
What conditions does trial NCT00090103 study?
This clinical trial studies the following conditions: Prostatic Hyperplasia.
What interventions are being tested in trial NCT00090103?
The interventions under investigation include: dutasteride 0.5mg once daily for 4 years (DRUG), tamsulosin 0.4mg once daily for 4 years (DRUG).
Who is sponsoring clinical trial NCT00090103?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00090103 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
RECRUITING · Phase 2
-
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
RECRUITING
-
Pelvic Floor Physical Therapy to Reduce Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
ACTIVE NOT RECRUITING · NA
-
Prostate Mechanical Imager (PMI) Clinical Bridging Study
COMPLETED
-
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
- NCT06307652 · 4,800 participants · Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia